MedTrace Logo

Association of Asprosin in Periodontitis and Acute Coronary Syndrome

NCT05647902 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-07-20

No results posted yet for this study

Summary

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between cardiovascular diseases and periodontitis. Investigators postulated that asprosin may be a candidate for explaining the triangular relationship between cardiovascular and periodontal disease.

Conditions

Interventions

DIAGNOSTIC_TEST

Serum samples will be collected. Asprosin levels will be determined by biochemical analysis

Serum samples will be collected from both groups for biochemical analysis.

Sponsors & Collaborators

  • Ataturk University

    lead OTHER

Principal Investigators

  • Oğuzhan Birdal, Asist. Prof. · Ataturk University

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-12-30
Completion
2023-01-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05647902 on ClinicalTrials.gov